Real-life study confirms that Metvix®-PDT is a cost-effective treatment

27. October 2008.
A recently published, Belgian real life practice study* confirms the efficacy and safety of Metvix demonstrated in previous randomised clinical trials (see abstract).

The study also shows that Metvix PDT is a cost-effective treatment in the management of actinic keratoses and basal cell carsinomas. The costs calculated from this study confirm the predicted cost-effectiveness shown in the original model**. This model has been adapted to local conditions and used in several countries to show that Metvix is a cost-effective treatment, among them Sweden and Norway.

Metvix is a registered trademark of Photocure ASA.

* Annemans et al. "Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma." Eur J Dermatol. 2008 Sep-Oct;18(5):539-46.
**Caekelbergh et al. “Economic evaluation of methyl aminolaevulinate-based photodynamic therapy in the management of actinic keratoses and basal cell carcinoma”. British Journal of Derm. 2006, 155, 784-790.